{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,14]],"date-time":"2026-09-14T21:49:28Z","timestamp":1789422568387,"version":"build-2803163510"},"reference-count":110,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T00:00:00Z","timestamp":1714521600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T00:00:00Z","timestamp":1714521600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,4,23]],"date-time":"2025-04-23T00:00:00Z","timestamp":1745366400000},"content-version":"am","delay-in-days":357,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","cghjournal.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Gastroenterology and Hepatology"],"published-print":{"date-parts":[[2024,5]]},"DOI":"10.1016\/j.cgh.2023.09.033","type":"journal-article","created":{"date-parts":[[2023,10,10]],"date-time":"2023-10-10T10:57:48Z","timestamp":1696935468000},"page":"961-970.e12","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":62,"title":["Risk of Major Adverse Cardiovascular Events in Immune-Mediated Inflammatory Disorders on Biologics and Small Molecules: Network Meta-Analysis"],"prefix":"10.1016","volume":"22","author":[{"given":"Shivani Shah","family":"Mattay","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohammad","family":"Zamani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dany","family":"Saturno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"suffix":"Jr.","given":"Edward V.","family":"Loftus","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew A.","family":"Ciorba","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andres","family":"Yarur","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Siddharth","family":"Singh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3436-9784","authenticated-orcid":false,"given":"Parakkal","family":"Deepak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.cgh.2023.09.033_bib1","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1093\/ecco-jcc\/jjv213","article-title":"The first European evidence-based consensus on extra-intestinal manifestations in inflammatory bowel disease","volume":"10","author":"Harbord","year":"2016","journal-title":"J\u00a0Crohns Colitis"},{"key":"10.1016\/j.cgh.2023.09.033_bib2","doi-asserted-by":"crossref","first-page":"4656","DOI":"10.1093\/rheumatology\/keac210","article-title":"All-cause and cause-specific mortality in rheumatoid arthritis, psoriatic arthritis and axial spondyloarthritis: a nationwide registry study","volume":"61","author":"Kerola","year":"2022","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.cgh.2023.09.033_bib3","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1016\/j.cgh.2022.08.035","article-title":"Inflammatory bowel disease is associated with an increased risk of incident acute arterial events: analysis of the United Kingdom Biobank","volume":"21","author":"Alayo","year":"2023","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.cgh.2023.09.033_bib4","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1136\/gutjnl-2012-303285","article-title":"Risk of ischaemic heart disease in patients with inflammatory bowel disease: a nationwide Danish cohort study","volume":"62","author":"Rungoe","year":"2013","journal-title":"Gut"},{"key":"10.1016\/j.cgh.2023.09.033_bib5","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1038\/nrrheum.2011.75","article-title":"Epidemiology of CVD in rheumatic disease, with a focus on RA and SLE","volume":"7","author":"Symmons","year":"2011","journal-title":"Nat Rev Rheumatol"},{"key":"10.1016\/j.cgh.2023.09.033_bib6","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1056\/NEJMoa2109927","article-title":"Cardiovascular and cancer risk with tofacitinib in rheumatoid arthritis","volume":"386","author":"Ytterberg","year":"2022","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.cgh.2023.09.033_bib7","doi-asserted-by":"crossref","first-page":"1208","DOI":"10.1001\/jamadermatol.2020.2977","article-title":"Association between early severe cardiovascular events and the initiation of treatment with the anti-interleukin 12\/23p40 antibody ustekinumab","volume":"156","author":"Poizeau","year":"2020","journal-title":"JAMA Dermatol"},{"key":"10.1016\/j.cgh.2023.09.033_bib8","doi-asserted-by":"crossref","first-page":"852","DOI":"10.1136\/gutjnl-2019-318932","article-title":"Risk of acute arterial events associated with treatment of inflammatory bowel diseases: nationwide French cohort study","volume":"69","author":"Kirchgesner","year":"2020","journal-title":"Gut"},{"key":"10.1016\/j.cgh.2023.09.033_bib9","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1136\/annrheumdis-2014-206624","article-title":"The effects of tumour necrosis factor inhibitors, methotrexate, non-steroidal anti-inflammatory drugs and corticosteroids on cardiovascular events in rheumatoid arthritis, psoriasis and psoriatic arthritis: a systematic review and meta-analysis","volume":"74","author":"Roubille","year":"2015","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.cgh.2023.09.033_bib10","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1136\/bmj.327.7414.557","article-title":"Measuring inconsistency in meta-analyses","volume":"327","author":"Higgins","year":"2003","journal-title":"BMJ"},{"key":"10.1016\/j.cgh.2023.09.033_bib11","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1002\/jrsm.1329","article-title":"Automated methods to test connectedness and quantify indirectness of evidence in network meta-analysis","volume":"10","author":"Thom","year":"2019","journal-title":"Res Synth Methods"},{"key":"10.1016\/j.cgh.2023.09.033_bib12","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1002\/jrsm.1167","article-title":"Automated generation of node-splitting models for assessment of inconsistency in network meta-analysis","volume":"7","author":"van Valkenhoef","year":"2016","journal-title":"Res Synth Methods"},{"key":"10.1016\/j.cgh.2023.09.033_bib13","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.1000097","article-title":"Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement","volume":"6","author":"Moher","year":"2009","journal-title":"PLoS Med"},{"key":"10.1016\/j.cgh.2023.09.033_bib14","doi-asserted-by":"crossref","first-page":"1004","DOI":"10.1136\/annrheumdis-2020-219601","article-title":"Tofacitinib for the treatment of ankylosing spondylitis: a phase III, randomised, double-blind, placebo-controlled study","volume":"80","author":"Deodhar","year":"2021","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.cgh.2023.09.033_bib15","doi-asserted-by":"crossref","first-page":"2108","DOI":"10.1016\/S0140-6736(19)32534-6","article-title":"Efficacy and safety of upadacitinib in patients with active ankylosing spondylitis (SELECT-AXIS 1): a multicentre, randomised, double-blind, placebo-controlled, phase 2\/3 trial","volume":"394","author":"van der Heijde","year":"2019","journal-title":"Lancet"},{"key":"10.1016\/j.cgh.2023.09.033_bib16","doi-asserted-by":"crossref","first-page":"2113","DOI":"10.1016\/S0140-6736(22)00581-5","article-title":"Upadacitinib as induction and maintenance therapy for moderately to severely active ulcerative colitis: results from three phase 3, multicentre, double-blind, randomised trials","volume":"399","author":"Danese","year":"2022","journal-title":"Lancet"},{"key":"10.1016\/j.cgh.2023.09.033_bib17","doi-asserted-by":"crossref","first-page":"2372","DOI":"10.1016\/S0140-6736(21)00666-8","article-title":"Filgotinib as induction and maintenance therapy for ulcerative colitis (SELECTION): a phase 2b\/3 double-blind, randomised, placebo-controlled trial","volume":"397","author":"Feagan","year":"2021","journal-title":"Lancet"},{"key":"10.1016\/j.cgh.2023.09.033_bib18","doi-asserted-by":"crossref","first-page":"2031","DOI":"10.1016\/S0140-6736(22)00466-4","article-title":"Risankizumab as maintenance therapy for moderately to severely active Crohn's disease: results from the multicentre, randomised, double-blind, placebo-controlled, withdrawal phase 3 FORTIFY maintenance trial","volume":"399","author":"Ferrante","year":"2022","journal-title":"Lancet"},{"key":"10.1016\/j.cgh.2023.09.033_bib19","doi-asserted-by":"crossref","first-page":"2123","DOI":"10.1053\/j.gastro.2020.01.047","article-title":"Efficacy and safety of upadacitinib in a randomized trial of patients with Crohn's disease","volume":"158","author":"Sandborn","year":"2020","journal-title":"Gastroenterology"},{"key":"10.1016\/j.cgh.2023.09.033_bib20","doi-asserted-by":"crossref","DOI":"10.1016\/S0016-5085(21)00834-9","article-title":"131 Safety of ustekinumab in IBD: a comprehensive analysis of major cardiovascular events (MACE) through 5 years in CD and 2 years in UC","volume":"160","author":"Ghosh","year":"2021","journal-title":"Gastroenterology"},{"key":"10.1016\/j.cgh.2023.09.033_bib21","doi-asserted-by":"crossref","first-page":"1541","DOI":"10.1016\/j.cgh.2018.11.035","article-title":"Safety of tofacitinib for treatment of ulcerative colitis, based on 4.4 years of data from global clinical trials","volume":"17","author":"Sandborn","year":"2019","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.cgh.2023.09.033_bib22","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1016\/S0140-6736(14)62113-9","article-title":"Tofacitinib versus etanercept or placebo in moderate-to-severe chronic plaque psoriasis: a phase 3 randomised non-inferiority trial","volume":"386","author":"Bachelez","year":"2015","journal-title":"Lancet"},{"key":"10.1016\/j.cgh.2023.09.033_bib23","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1016\/j.jaad.2016.11.041","volume":"76","author":"Blauvelt","year":"2017","journal-title":"J\u00a0Am Acad Dermatol"},{"key":"10.1016\/j.cgh.2023.09.033_bib24","doi-asserted-by":"crossref","first-page":"1115","DOI":"10.1016\/S0140-6736(20)30265-8","article-title":"Guselkumab in patients with active psoriatic arthritis who were biologic-naive or had previously received TNF\u03b1 inhibitor treatment (DISCOVER-1): a double-blind, randomised, placebo-controlled phase 3 trial","volume":"395","author":"Deodhar","year":"2020","journal-title":"Lancet"},{"key":"10.1016\/j.cgh.2023.09.033_bib25","doi-asserted-by":"crossref","first-page":"1387","DOI":"10.1002\/acr.23930","article-title":"Changes in lipid levels and incidence of cardiovascular events following tofacitinib treatment in patients with psoriatic arthritis: a pooled analysis across phase III and long-term extension studies","volume":"71","author":"Gladman","year":"2019","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"10.1016\/j.cgh.2023.09.033_bib26","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1177\/1203475416631329","article-title":"MACEs not associated with the use of biologic therapy for psoriasis in real-world clinical practice: a Canadian multicenter retrospective study","volume":"20","author":"Kim","year":"2016","journal-title":"J\u00a0Cutan Med Surg"},{"key":"10.1016\/j.cgh.2023.09.033_bib27","doi-asserted-by":"crossref","first-page":"1535","DOI":"10.1111\/jdv.12046","article-title":"Long-term efficacy of ustekinumab in patients with moderate-to-severe psoriasis treated for up to 5 years in the PHOENIX 1 study","volume":"27","author":"Kimball","year":"2013","journal-title":"J\u00a0Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.cgh.2023.09.033_bib28","doi-asserted-by":"crossref","first-page":"700","DOI":"10.1001\/jamadermatol.2019.0001","article-title":"Association of ustekinumab vs TNF inhibitor therapy with risk of atrial fibrillation and cardiovascular events in patients with psoriasis or psoriatic arthritis","volume":"155","author":"Lee","year":"2019","journal-title":"JAMA Dermatol"},{"key":"10.1016\/j.cgh.2023.09.033_bib29","doi-asserted-by":"crossref","DOI":"10.1136\/rmdopen-2021-001838","article-title":"Upadacitinib in patients with psoriatic arthritis and an inadequate response to non-biological therapy: 56-week data from the phase 3 SELECT-PsA 1 study","volume":"7","author":"McInnes","year":"2021","journal-title":"RMD Open"},{"key":"10.1016\/j.cgh.2023.09.033_bib30","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1002\/acr.23738","article-title":"Safety of ixekizumab in patients with psoriatic arthritis: results from a pooled analysis of three clinical trials","volume":"71","author":"Mease","year":"2019","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"10.1016\/j.cgh.2023.09.033_bib31","doi-asserted-by":"crossref","first-page":"1126","DOI":"10.1016\/S0140-6736(20)30263-4","article-title":"Guselkumab in biologic-naive patients with active psoriatic arthritis (DISCOVER-2): a double-blind, randomised, placebo-controlled phase 3 trial","volume":"395","author":"Mease","year":"2020","journal-title":"Lancet"},{"key":"10.1016\/j.cgh.2023.09.033_bib32","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1136\/annrheumdis-2020-218870","article-title":"Upadacitinib for psoriatic arthritis refractory to biologics: SELECT-PsA 2","volume":"80","author":"Mease","year":"2021","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.cgh.2023.09.033_bib33","doi-asserted-by":"crossref","first-page":"1361","DOI":"10.1007\/s40744-022-00474-5","article-title":"Long-term efficacy and safety of risankizumab in patients with active psoriatic arthritis: results from a 76-week phase 2 randomized trial","volume":"9","author":"Mease","year":"2022","journal-title":"Rheumatol Ther"},{"key":"10.1016\/j.cgh.2023.09.033_bib34","first-page":"706","article-title":"Safety surveillance for ustekinumab and other psoriasis treatments from the Psoriasis Longitudinal Assessment and Registry (PSOLAR)","volume":"14","author":"Papp","year":"2015","journal-title":"J\u00a0Drugs Dermatol"},{"key":"10.1016\/j.cgh.2023.09.033_bib35","doi-asserted-by":"crossref","first-page":"1589","DOI":"10.1093\/rheumatology\/keab522","article-title":"Risk of major adverse cardiovascular events in patients initiating biologics\/apremilast for psoriatic arthritis: a nationwide cohort study","volume":"61","author":"Pina Vegas","year":"2022","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.cgh.2023.09.033_bib36","doi-asserted-by":"crossref","first-page":"862","DOI":"10.1111\/j.1365-2133.2011.10257.x","article-title":"Cardiovascular safety of ustekinumab in patients with moderate to severe psoriasis: results of integrated analyses of data from phase II and III clinical studies","volume":"164","author":"Reich","year":"2011","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.cgh.2023.09.033_bib37","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1016\/j.jaad.2016.11.042","volume":"76","author":"Reich","year":"2017","journal-title":"J\u00a0Am Acad Dermatol"},{"key":"10.1016\/j.cgh.2023.09.033_bib38","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1111\/bjd.18232","article-title":"Long-term efficacy and safety of tildrakizumab for moderate-to-severe psoriasis: pooled analyses of two randomized phase III clinical trials (re SURFACE 1 and re SURFACE 2) through 148 weeks","volume":"182","author":"Reich","year":"2020","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.cgh.2023.09.033_bib39","doi-asserted-by":"crossref","first-page":"990","DOI":"10.1136\/annrheumdis-2013-204655","volume":"73","author":"Ritchlin","year":"2014","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.cgh.2023.09.033_bib40","first-page":"166","article-title":"Efficacy and safety of ustekinumab in Chinese patients with moderate to severe plaque-type psoriasis: results from a phase 3 clinical trial (LOTUS)","volume":"12","author":"Zhu","year":"2013","journal-title":"J\u00a0Drugs Dermatol"},{"key":"10.1016\/j.cgh.2023.09.033_bib41","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1016\/S0140-6736(15)60125-8","article-title":"Comparison of ixekizumab with etanercept or placebo in moderate-to-severe psoriasis (UNCOVER-2 and UNCOVER-3): results from two phase 3 randomised trials","volume":"386","author":"Griffiths","year":"2015","journal-title":"Lancet"},{"issue":"suppl 9","key":"10.1016\/j.cgh.2023.09.033_bib42","article-title":"Risk of extended major adverse cardiovascular event endpoints with tofacitinib vs TNF inhibitors in patients with rheumatoid arthritis: a post hoc analysis of a phase 3b\/4 randomized safety study [abstract]","volume":"74","author":"Buch","year":"2022","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.cgh.2023.09.033_bib43","first-page":"735","article-title":"FRI0132 LONG-term safety and efficacy of upadacitinib in patients with rheumatoid arthritis and an inadequate response to csDMARDS: results at 60 weeks from the SELECT-NEXT study","volume":"78","author":"Burmester","year":"2019","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.cgh.2023.09.033_bib44","doi-asserted-by":"crossref","DOI":"10.1136\/rmdopen-2020-001395","article-title":"Long-term safety of tofacitinib up to 9.5 years: a comprehensive integrated analysis of the rheumatoid arthritis clinical development programme","volume":"6","author":"Cohen","year":"2020","journal-title":"RMD Open"},{"key":"10.1016\/j.cgh.2023.09.033_bib45","doi-asserted-by":"crossref","first-page":"848","DOI":"10.1136\/annrheumdis-2020-219214","article-title":"Filgotinib versus placebo or adalimumab in patients with rheumatoid arthritis and inadequate response to methotrexate: a phase III randomised clinical trial","volume":"80","author":"Combe","year":"2021","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.cgh.2023.09.033_bib46","doi-asserted-by":"crossref","DOI":"10.1136\/rmdopen-2021-002012","article-title":"Long-term safety and efficacy of upadacitinib or adalimumab in patients with rheumatoid arthritis: results through 3 years from the SELECT-COMPARE study","volume":"8","author":"Fleischmann","year":"2022","journal-title":"RMD Open"},{"key":"10.1016\/j.cgh.2023.09.033_bib47","doi-asserted-by":"crossref","first-page":"2513","DOI":"10.1016\/S0140-6736(18)31116-4","article-title":"Safety and efficacy of upadacitinib in patients with active rheumatoid arthritis refractory to biologic disease-modifying anti-rheumatic drugs (SELECT-BEYOND): a double-blind, randomised controlled phase 3 trial","volume":"391","author":"Genovese","year":"2018","journal-title":"Lancet"},{"key":"10.1016\/j.cgh.2023.09.033_bib48","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1002\/art.41095","article-title":"Cardiovascular safety of tocilizumab versus etanercept in rheumatoid arthritis: a randomized controlled trial","volume":"72","author":"Giles","year":"2020","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.cgh.2023.09.033_bib49","doi-asserted-by":"crossref","first-page":"2303","DOI":"10.1016\/S0140-6736(19)30419-2","article-title":"Upadacitinib as monotherapy in patients with active rheumatoid arthritis and inadequate response to methotrexate (SELECT-MONOTHERAPY): a randomised, placebo-controlled, double-blind phase 3 study","volume":"393","author":"Smolen","year":"2019","journal-title":"Lancet"},{"key":"10.1016\/j.cgh.2023.09.033_bib50","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1056\/NEJMoa1112072","article-title":"Tofacitinib or adalimumab versus placebo in rheumatoid arthritis","volume":"367","author":"van Vollenhoven","year":"2012","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.cgh.2023.09.033_bib51","doi-asserted-by":"crossref","first-page":"1607","DOI":"10.1002\/art.41384","article-title":"Efficacy and Safety of Upadacitinib Monotherapy in Methotrexate-naive patients with Moderately-to-Severely Active Rheumatoid Arthritis (SELECT-EARLY): a multicenter, multi-country, randomized, double-blind, active comparator\u2013controlled trial","volume":"72","author":"van Vollenhoven","year":"2020","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.cgh.2023.09.033_bib52","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1136\/annrheumdis-2021-221051","article-title":"Integrated safety analysis of filgotinib in patients with moderately to severely active rheumatoid arthritis receiving treatment over a median of 1.6 years","volume":"81","author":"Winthrop","year":"2022","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.cgh.2023.09.033_bib53","doi-asserted-by":"crossref","DOI":"10.1136\/rmdopen-2019-000942","article-title":"Long-term safety of certolizumab pegol in rheumatoid arthritis, axial spondyloarthritis, psoriatic arthritis, psoriasis and Crohn\u2019s disease: a pooled analysis of 11 317 patients across clinical trials","volume":"5","author":"Curtis","year":"2019","journal-title":"RMD Open"},{"key":"10.1016\/j.cgh.2023.09.033_bib54","doi-asserted-by":"crossref","first-page":"1554","DOI":"10.1053\/j.gastro.2020.01.001","article-title":"Safety of Janus kinase inhibitors in patients with inflammatory bowel diseases or other immune-mediated diseases: a systematic review and meta-analysis","volume":"158","author":"Olivera","year":"2020","journal-title":"Gastroenterology"},{"key":"10.1016\/j.cgh.2023.09.033_bib55","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1007\/s12016-016-8560-9","article-title":"The effect of TNF inhibitors on cardiovascular events in psoriasis and psoriatic arthritis: an updated meta-analysis","volume":"51","author":"Yang","year":"2016","journal-title":"Clin Rev Allergy Immunol"},{"key":"10.1016\/j.cgh.2023.09.033_bib56","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1007\/s11739-016-1583-7","article-title":"Network meta-analysis: an introduction for clinicians","volume":"12","author":"Rouse","year":"2017","journal-title":"Intern Emerg Med"},{"key":"10.1016\/j.cgh.2023.09.033_bib57","doi-asserted-by":"crossref","first-page":"943","DOI":"10.18549\/PharmPract.2017.01.943","article-title":"Network meta-analysis: a technique to gather evidence from direct and indirect comparisons","volume":"15","author":"Tonin","year":"2017","journal-title":"Pharm Pract (Granada)"},{"key":"10.1016\/j.cgh.2023.09.033_bib58","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1002\/jrsm.1195","article-title":"GetReal in network meta-analysis: a review of the methodology","volume":"7","author":"Efthimiou","year":"2016","journal-title":"Res Synth Methods"},{"key":"10.1016\/j.cgh.2023.09.033_bib59","doi-asserted-by":"crossref","first-page":"1231","DOI":"10.1111\/apt.17509","article-title":"Review article: Risk of cardiovascular events in patients with inflammatory bowel disease receiving small molecule drugs","volume":"57","author":"Olivera","year":"2023","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.cgh.2023.09.033_bib60","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1080\/17474124.2023.2194631","article-title":"Impact of biologic therapies and small molecules on the risk of major adverse cardiovascular events in patients with inflammatory bowel diseases: systematic review and meta-analysis of randomised controlled trials","volume":"17","author":"Shehab","year":"2023","journal-title":"Expert Rev Gastroenterol Hepatol"},{"key":"10.1016\/j.cgh.2023.09.033_bib61","article-title":"Vedolizumab in Japanese patients with ulcerative colitis: a phase 3, randomized, double-blind, placebo-controlled study","volume":"14","author":"Motoya","year":"2019","journal-title":"PLoS One"},{"key":"10.1016\/j.cgh.2023.09.033_bib62","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1007\/s00535-019-01647-w","article-title":"Effects of vedolizumab in Japanese patients with Crohn's disease: a prospective, multicenter, randomized, placebo-controlled phase 3 trial with exploratory analyses","volume":"55","author":"Watanabe","year":"2020","journal-title":"J\u00a0Gastroenterol"},{"key":"10.1016\/j.cgh.2023.09.033_bib63","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1016\/S0140-6736(22)01349-6","article-title":"Autoimmune diseases and cardiovascular risk: a population-based study on 19 autoimmune diseases and 12 cardiovascular diseases in 22 million individuals in the UK","volume":"400","author":"Conrad","year":"2022","journal-title":"Lancet"},{"key":"10.1016\/j.cgh.2023.09.033_bib64","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.1056\/NEJMoa1707914","article-title":"Antiinflammatory therapy with canakinumab for atherosclerotic disease","volume":"377","author":"Ridker","year":"2017","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.cgh.2023.09.033_bib65","article-title":"Cardiovascular risk associated with TNF alpha inhibitor use in patients with rheumatoid arthritis","volume":"13","author":"Hussain","year":"2021","journal-title":"Cureus"},{"key":"10.1016\/j.cgh.2023.09.033_bib66","first-page":"864","article-title":"Association between biologic therapies for chronic plaque psoriasis and cardiovascular events: a meta-analysis of randomized controlled trials","volume":"306","author":"Ryan","year":"2011","journal-title":"JAMA"},{"key":"10.1016\/j.cgh.2023.09.033_bib67","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1089\/jir.2018.0006","article-title":"Interleukin-23: a new atherosclerosis target","volume":"38","author":"Liu","year":"2018","journal-title":"J\u00a0Interferon Cytokine Res"},{"key":"10.1016\/j.cgh.2023.09.033_bib68","doi-asserted-by":"crossref","first-page":"3358","DOI":"10.1093\/rheumatology\/kead079","article-title":"Comparison of risks of cancer, infection, and MACEs associated with JAK inhibitor and TNF inhibitor treatment: a multicenter cohort study","volume":"62","author":"Uchida","year":"2023","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.cgh.2023.09.033_bib69","doi-asserted-by":"crossref","first-page":"798","DOI":"10.1136\/annrheumdis-2021-221915","article-title":"Tofacitinib and risk of cardiovascular outcomes: results from the Safety of TofAcitinib in Routine care patients with Rheumatoid Arthritis (STAR-RA) study","volume":"81","author":"Khosrow-Khavar","year":"2022","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.cgh.2023.09.033_bib70","doi-asserted-by":"crossref","first-page":"1004","DOI":"10.1136\/annrheumdis-2020-219601","article-title":"Tofacitinib for the treatment of ankylosing spondylitis: a phase III, randomised, double-blind, placebo-controlled study","volume":"80","author":"Deodhar","year":"2021","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.cgh.2023.09.033_bib71","doi-asserted-by":"crossref","first-page":"2108","DOI":"10.1016\/S0140-6736(19)32534-6","article-title":"Efficacy and safety of upadacitinib in patients with active ankylosing spondylitis (SELECT-AXIS 1): a multicentre, randomised, double-blind, placebo-controlled, phase 2\/3 trial","volume":"394","author":"van der Heijde","year":"2019","journal-title":"Lancet"},{"key":"10.1016\/j.cgh.2023.09.033_bib72","doi-asserted-by":"crossref","first-page":"2113","DOI":"10.1016\/S0140-6736(22)00581-5","article-title":"Upadacitinib as induction and maintenance therapy for moderately to severely active ulcerative colitis: results from three phase 3, multicentre, double-blind, randomised trials","volume":"399","author":"Danese","year":"2022","journal-title":"Lancet"},{"key":"10.1016\/j.cgh.2023.09.033_bib73","doi-asserted-by":"crossref","first-page":"2372","DOI":"10.1016\/S0140-6736(21)00666-8","article-title":"Filgotinib as induction and maintenance therapy for ulcerative colitis (SELECTION): a phase 2b\/3 double-blind, randomised, placebo-controlled trial","volume":"397","author":"Feagan","year":"2021","journal-title":"Lancet"},{"key":"10.1016\/j.cgh.2023.09.033_bib74","doi-asserted-by":"crossref","first-page":"2031","DOI":"10.1016\/S0140-6736(22)00466-4","article-title":"Risankizumab as maintenance therapy for moderately to severely active Crohn's disease: results from the multicentre, randomised, double-blind, placebo-controlled, withdrawal phase 3 FORTIFY maintenance trial","volume":"399","author":"Ferrante","year":"2022","journal-title":"Lancet"},{"key":"10.1016\/j.cgh.2023.09.033_bib75","doi-asserted-by":"crossref","DOI":"10.1016\/S0016-5085(21)00834-9","article-title":"131 SAFETY of ustekinumab in IBD: a comprehensive analysis of major cardiovascular events (MACE) through 5 years in CD and 2 years in UC","volume":"160","author":"Ghosh","year":"2021","journal-title":"Gastroenterology"},{"key":"10.1016\/j.cgh.2023.09.033_bib76","doi-asserted-by":"crossref","first-page":"1541","DOI":"10.1016\/j.cgh.2018.11.035","article-title":"Safety of tofacitinib for treatment of ulcerative colitis, based on 4.4 years of data from global clinical trials","volume":"17","author":"Sandborn","year":"2019","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.cgh.2023.09.033_bib77","doi-asserted-by":"crossref","first-page":"2123","DOI":"10.1053\/j.gastro.2020.01.047","article-title":"Efficacy and safety of upadacitinib in a randomized trial of patients with Crohn's disease","volume":"158","author":"Sandborn","year":"2020","journal-title":"Gastroenterology"},{"key":"10.1016\/j.cgh.2023.09.033_bib78","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1016\/S0140-6736(14)62113-9","article-title":"Tofacitinib versus etanercept or placebo in moderate-to-severe chronic plaque psoriasis: a phase 3 randomised non-inferiority trial","volume":"386","author":"Bachelez","year":"2015","journal-title":"Lancet"},{"key":"10.1016\/j.cgh.2023.09.033_bib79","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1016\/j.jaad.2016.11.041","volume":"76","author":"Blauvelt","year":"2017","journal-title":"J\u00a0Am Acad Dermatol"},{"key":"10.1016\/j.cgh.2023.09.033_bib80","doi-asserted-by":"crossref","first-page":"1115","DOI":"10.1016\/S0140-6736(20)30265-8","article-title":"Guselkumab in patients with active psoriatic arthritis who were biologic-naive or had previously received TNF\u03b1 inhibitor treatment (DISCOVER-1): a double-blind, randomised, placebo-controlled phase 3 trial","volume":"395","author":"Deodhar","year":"2020","journal-title":"Lancet"},{"key":"10.1016\/j.cgh.2023.09.033_bib81","doi-asserted-by":"crossref","first-page":"1387","DOI":"10.1002\/acr.23930","article-title":"Changes\u00a0in lipid levels and incidence of cardiovascular events\u00a0following tofacitinib treatment in patients with psoriatic arthritis: a pooled analysis across phase III and long-term extension studies","volume":"71","author":"Gladman","year":"2019","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"10.1016\/j.cgh.2023.09.033_bib82","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1016\/S0140-6736(15)60125-8","article-title":"Comparison of ixekizumab with etanercept or placebo in moderate-to-severe psoriasis (UNCOVER-2 and UNCOVER-3): results from two phase 3 randomised trials","volume":"386","author":"Griffiths","year":"2015","journal-title":"Lancet"},{"key":"10.1016\/j.cgh.2023.09.033_bib83","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1177\/1203475416631329","article-title":"MACEs not associated with the use of biologic therapy for psoriasis in real-world clinical practice: a Canadian multicenter retrospective study","volume":"20","author":"Kim","year":"2016","journal-title":"J\u00a0Cutaneous Med Surg"},{"key":"10.1016\/j.cgh.2023.09.033_bib84","doi-asserted-by":"crossref","first-page":"700","DOI":"10.1001\/jamadermatol.2019.0001","article-title":"Association of ustekinumab vs TNF inhibitor therapy with risk of atrial fibrillation and cardiovascular events in patients with psoriasis or psoriatic arthritis","volume":"155","author":"Lee","year":"2019","journal-title":"JAMA Dermatol"},{"key":"10.1016\/j.cgh.2023.09.033_bib85","doi-asserted-by":"crossref","first-page":"1665","DOI":"10.1016\/S0140-6736(08)60725-4","article-title":"Efficacy and safety of ustekinumab, a human interleukin-12\/23 monoclonal antibody, in patients with psoriasis: 76-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 1)","volume":"371","author":"Leonardi","year":"2008","journal-title":"Lancet"},{"key":"10.1016\/j.cgh.2023.09.033_bib86","doi-asserted-by":"crossref","DOI":"10.1136\/rmdopen-2021-001838","article-title":"Upadacitinib in patients with psoriatic arthritis and an inadequate response to non-biological therapy: 56-week data from the phase 3 SELECT-PsA 1 study","volume":"7","author":"McInnes","year":"2021","journal-title":"RMD Open"},{"key":"10.1016\/j.cgh.2023.09.033_bib87","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1136\/annrheumdis-2016-209709","volume":"76","author":"Mease","year":"2017","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.cgh.2023.09.033_bib88","doi-asserted-by":"crossref","first-page":"1126","DOI":"10.1016\/S0140-6736(20)30263-4","article-title":"Guselkumab in biologic-naive patients with active psoriatic arthritis (DISCOVER-2): a double-blind, randomised, placebo-controlled phase 3 trial","volume":"395","author":"Mease","year":"2020","journal-title":"Lancet"},{"key":"10.1016\/j.cgh.2023.09.033_bib89","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1136\/annrheumdis-2020-218870","article-title":"Upadacitinib for psoriatic arthritis refractory to biologics: SELECT-PsA 2","volume":"80","author":"Mease","year":"2021","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.cgh.2023.09.033_bib90","doi-asserted-by":"crossref","first-page":"1361","DOI":"10.1007\/s40744-022-00474-5","article-title":"Long-term efficacy and safety of risankizumab in patients with active psoriatic arthritis: results from a 76-week phase 2 randomized trial","volume":"9","author":"Mease","year":"2022","journal-title":"Rheumatol Ther"},{"key":"10.1016\/j.cgh.2023.09.033_bib91","first-page":"706","article-title":"Safety surveillance for ustekinumab and other psoriasis treatments from the Psoriasis Longitudinal Assessment and Registry (PSOLAR)","volume":"14","author":"Papp","year":"2015","journal-title":"J\u00a0Drugs Dermatol"},{"key":"10.1016\/j.cgh.2023.09.033_bib92","doi-asserted-by":"crossref","first-page":"1551","DOI":"10.1056\/NEJMoa1607017","article-title":"Risankizumab versus ustekinumab for moderate-to-severe plaque psoriasis","volume":"376","author":"Papp","year":"2017","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.cgh.2023.09.033_bib93","doi-asserted-by":"crossref","first-page":"1589","DOI":"10.1093\/rheumatology\/keab522","article-title":"Risk of major adverse cardiovascular events in patients initiating biologics\/apremilast for psoriatic arthritis: a nationwide cohort study","volume":"61","author":"Pina Vegas","year":"2022","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.cgh.2023.09.033_bib94","doi-asserted-by":"crossref","first-page":"862","DOI":"10.1111\/j.1365-2133.2011.10257.x","article-title":"Cardiovascular safety of ustekinumab in patients with moderate to severe psoriasis: results of integrated analyses of data from phase II and III clinical studies","volume":"164","author":"Reich","year":"2011","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.cgh.2023.09.033_bib95","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1016\/j.jaad.2016.11.042","volume":"76","author":"Reich","year":"2017","journal-title":"J\u00a0Am Acad Dermatol"},{"key":"10.1016\/j.cgh.2023.09.033_bib96","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1111\/bjd.18232","article-title":"Long-term efficacy and safety of tildrakizumab for moderate-to-severe psoriasis: pooled analyses of two randomized phase III clinical trials (re SURFACE 1 and re SURFACE 2) through 148 weeks","volume":"182","author":"Reich","year":"2020","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.cgh.2023.09.033_bib97","doi-asserted-by":"crossref","first-page":"990","DOI":"10.1136\/annrheumdis-2013-204655","volume":"73","author":"Ritchlin","year":"2014","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.cgh.2023.09.033_bib98","first-page":"166","article-title":"Efficacy and safety of ustekinumab in Chinese patients with moderate to severe plaque-type psoriasis: results from a phase 3 clinical trial (LOTUS)","volume":"12","author":"Zhu","year":"2013","journal-title":"J\u00a0Drugs Dermatol"},{"key":"10.1016\/j.cgh.2023.09.033_bib99","doi-asserted-by":"crossref","first-page":"2503","DOI":"10.1016\/S0140-6736(18)31115-2","article-title":"Safety and efficacy of upadacitinib in patients with rheumatoid arthritis and inadequate response to conventional synthetic disease-modifying anti-rheumatic drugs (SELECT-NEXT): a randomised, double-blind, placebo-controlled phase 3 trial","volume":"391","author":"Burmester","year":"2018","journal-title":"Lancet"},{"key":"10.1016\/j.cgh.2023.09.033_bib100","doi-asserted-by":"crossref","DOI":"10.1136\/rmdopen-2020-001395","article-title":"Long-term safety of tofacitinib up to 9.5 years: a comprehensive integrated analysis of the rheumatoid arthritis clinical development programme","volume":"6","author":"Cohen","year":"2020","journal-title":"RMD Open"},{"key":"10.1016\/j.cgh.2023.09.033_bib101","doi-asserted-by":"crossref","first-page":"848","DOI":"10.1136\/annrheumdis-2020-219214","article-title":"Filgotinib versus placebo or adalimumab in patients with rheumatoid arthritis and inadequate response to methotrexate: a phase III randomised clinical trial","volume":"80","author":"Combe","year":"2021","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.cgh.2023.09.033_bib102","doi-asserted-by":"crossref","DOI":"10.1136\/rmdopen-2021-002012","article-title":"Long-term safety and efficacy of upadacitinib or adalimumab in patients with rheumatoid arthritis: results through 3 years from the SELECT-COMPARE study","volume":"8","author":"Fleischmann","year":"2022","journal-title":"RMD Open"},{"key":"10.1016\/j.cgh.2023.09.033_bib103","doi-asserted-by":"crossref","first-page":"2513","DOI":"10.1016\/S0140-6736(18)31116-4","article-title":"Safety and efficacy of upadacitinib in patients with active rheumatoid arthritis refractory to biologic disease-modifying anti-rheumatic drugs (SELECT-BEYOND): a double-blind, randomised controlled phase 3 trial","volume":"391","author":"Genovese","year":"2018","journal-title":"Lancet"},{"key":"10.1016\/j.cgh.2023.09.033_bib104","doi-asserted-by":"crossref","first-page":"2303","DOI":"10.1016\/S0140-6736(19)30419-2","article-title":"Upadacitinib as monotherapy in patients with active rheumatoid arthritis and inadequate response to methotrexate (SELECT-MONOTHERAPY): a randomised, placebo-controlled, double-blind phase 3 study","volume":"393","author":"Smolen","year":"2019","journal-title":"Lancet"},{"key":"10.1016\/j.cgh.2023.09.033_bib105","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1056\/NEJMoa1112072","article-title":"Tofacitinib or adalimumab versus placebo in rheumatoid arthritis","volume":"367","author":"van Vollenhoven","year":"2012","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.cgh.2023.09.033_bib106","doi-asserted-by":"crossref","first-page":"1607","DOI":"10.1002\/art.41384","article-title":"Efficacy and Safety of Upadacitinib Monotherapy in Methotrexate-naive patients with Moderately-to-Severely Active Rheumatoid Arthritis (SELECT-EARLY): a multicenter, multi-country, randomized, double-blind, active comparator\u2013controlled trial","volume":"72","author":"van Vollenhoven","year":"2020","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.cgh.2023.09.033_bib107","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1136\/annrheumdis-2021-221051","article-title":"Integrated safety analysis of filgotinib in patients with moderately to severely active rheumatoid arthritis receiving treatment over a median of 1.6 years","volume":"81","author":"Winthrop","year":"2022","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.cgh.2023.09.033_bib108","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1056\/NEJMoa2109927","article-title":"Cardiovascular and cancer risk with tofacitinib in rheumatoid arthritis","volume":"386","author":"Ytterberg","year":"2022","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.cgh.2023.09.033_bib109","doi-asserted-by":"crossref","DOI":"10.1136\/rmdopen-2019-000942","article-title":"Long-term safety of certolizumab pegol in rheumatoid arthritis, axial spondyloarthritis, psoriatic arthritis, psoriasis and Crohn\u2019s disease: a pooled analysis of 11 317 patients across clinical trials","volume":"5","author":"Curtis","year":"2019","journal-title":"Rmd Open"},{"key":"10.1016\/j.cgh.2023.09.033_bib110","doi-asserted-by":"crossref","first-page":"618","DOI":"10.1177\/0272989X13485157","article-title":"Evidence synthesis for decision making 3: heterogeneity--subgroups, meta-regression, bias, and bias-adjustment","volume":"33","author":"Dias","year":"2013","journal-title":"Med Decis Making"}],"container-title":["Clinical Gastroenterology and Hepatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S154235652300767X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S154235652300767X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,11,9]],"date-time":"2024-11-09T01:11:42Z","timestamp":1731114702000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S154235652300767X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,5]]},"references-count":110,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2024,5]]}},"alternative-id":["S154235652300767X"],"URL":"https:\/\/doi.org\/10.1016\/j.cgh.2023.09.033","relation":{},"ISSN":["1542-3565"],"issn-type":[{"value":"1542-3565","type":"print"}],"subject":[],"published":{"date-parts":[[2024,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Risk of Major Adverse Cardiovascular Events in Immune-Mediated Inflammatory Disorders on Biologics and Small Molecules: Network Meta-Analysis","name":"articletitle","label":"Article Title"},{"value":"Clinical Gastroenterology and Hepatology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cgh.2023.09.033","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 by the AGA Institute","name":"copyright","label":"Copyright"}]}}